Seiichiro Sakao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/822490/publications.pdf

Version: 2024-02-01

104 papers 2,206 citations

304602 22 h-index 42 g-index

104 all docs

 $\begin{array}{c} 104 \\ \\ \text{docs citations} \end{array}$

104 times ranked

2849 citing authors

#	Article	IF	Citations
1	Pulmonary Veno-occlusive Disease that Developed Following Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia. Internal Medicine, 2023, 62, 275-279.	0.3	1
2	Selexipag for the treatment of chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2022, 60, 2101694.	3.1	26
3	Multi‑omics analysis of right ventricles in rat models of pulmonary arterial hypertension: Consideration of mitochondrial biogenesis by chrysin. International Journal of Molecular Medicine, 2022, 49, .	1.8	3
4	Tolerability of prone positioning in nonâ€intubated patients with hypoxaemia due to <scp>COVID</scp> â€i 9â€related pneumonia. Respirology, 2022, 27, 370-371.	1.3	4
5	Altered gut microbiota and its association with inflammation in patients with chronic thromboembolic pulmonary hypertension: a single-center observational study in Japan. BMC Pulmonary Medicine, 2022, 22, 138.	0.8	8
6	The Isoquinoline-Sulfonamide Compound H-1337 Attenuates SU5416/Hypoxia-Induced Pulmonary Arterial Hypertension in Rats. Cells, 2022, $11,66$.	1.8	5
7	Case of a Deep Neck Abscess During Treatment for COVID-19. American Journal of Case Reports, 2022, 23, e936034.	0.3	3
8	Pneumocystis pneumonia in an immunocompetent patient developing a subacute disease course with central consolidation. Respiratory Medicine Case Reports, 2022, 37, 101659.	0.2	0
9	Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike. Cell, 2022, 185, 2103-2115.e19.	13.5	273
10	Metabolic remodeling in the right ventricle of rats with severe pulmonary arterial hypertension. Molecular Medicine Reports, $2021, 23, \ldots$	1.1	11
11	Heritable pulmonary arterial hypertension complicated by multiple pulmonary arteriovenous malformations. Respiratory Medicine Case Reports, 2021, 32, 101352.	0.2	0
12	Yellow nail syndrome with massive chylothorax after esophagectomy: A case report. Respiratory Medicine Case Reports, 2021, 33, 101448.	0.2	1
13	The clinical characteristics, treatment, and survival of portopulmonary hypertension in Japan. BMC Pulmonary Medicine, 2021, 21, 89.	0.8	7
14	Alternative approaches for clinical clerkship during the COVID-19 pandemic: online simulated clinical practice for inpatients and outpatientsâ€"A mixed method. BMC Medical Education, 2021, 21, 149.	1.0	31
15	Drug Fever Due to Favipiravir Administration for the Treatment of a COVID-19 Patient. Internal Medicine, 2021, 60, 1115-1117.	0.3	2
16	Cell Tracking Suggests Pathophysiological and Therapeutic Role of Bone Marrow Cells in Sugen5416/Hypoxia Rat Model of Pulmonary Arterial Hypertension. Canadian Journal of Cardiology, 2021, 37, 913-923.	0.8	0
17	Serum anti-DIDO1, anti-CPSF2, and anti-FOXJ2 antibodies as predictive risk markers for acute ischemic stroke. BMC Medicine, 2021, 19, 131.	2.3	13

Characteristics of patients meeting the new definition of pre-capillary pulmonary hypertension (Nice) Tj ETQq0 0 0 0 ggBT /Overlock 10 Tf

#	Article	IF	Citations
19	Six Cases of Hemoptysis with Angiogenesis from Non-Bronchial Systemic Arteries. American Journal of Case Reports, 2021, 22, e933187.	0.3	2
20	A case of pulmonary arterial hypertension with V/Q SPECT / CT that showed localized uptake of 99mTc just below the pleura and a unique distribution. Respirology Case Reports, 2021, 9, e0847.	0.3	0
21	Possibility of deterioration of respiratory status when steroids precede antiviral drugs in patients with COVID-19 pneumonia: A retrospective study. PLoS ONE, 2021, 16, e0256977.	1.1	14
22	Interventricular septal curvature as an additional echocardiographic parameter for evaluating chronic thromboembolic pulmonary hypertension: a single-center retrospective study. BMC Pulmonary Medicine, 2021, 21, 328.	0.8	1
23	Vascular involvement in chronic thromboembolic pulmonary hypertension is associated with spirometry obstructive impairment. BMC Pulmonary Medicine, 2021, 21, 407.	0.8	7
24	Pulmonary hypertension with a low cardiac index requires a higher PaO 2 level to avoid tissue hypoxia. Respirology, 2020, 25, 97-103.	1.3	4
25	Protective role of endothelial progenitor cells stimulated by riociguat in chronic thromboembolic pulmonary hypertension. International Journal of Cardiology, 2020, 299, 263-270.	0.8	12
26	Characteristics of Japanese elderly patients with pulmonary arterial hypertension. Pulmonary Circulation, 2020, 10, 1-13.	0.8	6
27	Effects of pulmonary endarterectomy on pulmonary hemodynamics in chronic thromboembolic pulmonary hypertension, evaluated by interventricular septum curvature. Pulmonary Circulation, 2020, 10, 1-9.	0.8	3
28	The extent of enlarged bronchial arteries is not correlated with the development of reperfusion pulmonary edema after pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension. Pulmonary Circulation, 2020, 10, 1-5.	0.8	1
29	Reply to letter to Editor. International Journal of Cardiology, 2020, 307, 164.	0.8	0
30	Gut microbiota modification suppresses the development of pulmonary arterial hypertension in an SU5416/hypoxia rat model. Pulmonary Circulation, 2020, 10, 1-10.	0.8	32
31	Severe thrombocytopenia in patients with idiopathic pulmonary arterial hypertension provided several strategies for lung transplantation. Pulmonary Circulation, 2020, 10, 1-4.	0.8	4
32	Circulating Anti-Sorting Nexins 16 Antibodies as an Emerging Biomarker of Coronary Artery Disease in Patients with Obstructive Sleep Apnea. Diagnostics, 2020, 10, 71.	1.3	7
33	Chronic lung disease-associated PH: PAH-approved drugs and established universal healthcare insurance in Japan. Respiratory Investigation, 2020, 58, 230-231.	0.9	0
34	Nocturnal Hypoxemia and High Circulating TNF- \hat{l}_{\pm} Levels in Chronic Thromboembolic Pulmonary Hypertension. Internal Medicine, 2020, 59, 1819-1826.	0.3	10
35	Acute Eosinophilic Pneumonia and Heated Tobacco Products. Internal Medicine, 2020, 59, 2807-2807.	0.3	3
36	Pulmonary Hypertension that Developed During Treatment for Hepatopulmonary Syndrome and Pulmonary Arteriovenous Malformation. Internal Medicine, 2019, 58, 1765-1769.	0.3	6

3

#	Article	IF	CITATIONS
37	Chronic obstructive pulmonary disease and the early stage of cor pulmonale: A perspective in treatment with pulmonary arterial hypertension-approved drugs. Respiratory Investigation, 2019, 57, 325-329.	0.9	13
38	Chronic thromboembolic pulmonary hypertension in Austria and Japan. Journal of Thoracic and Cardiovascular Surgery, 2019, 158, 604-614.e2.	0.4	30
39	The updated classification of PVOD/PCH: A slight but meaningful change. Respiratory Investigation, 2019, 57, 408-409.	0.9	0
40	Involvement of pulmonary arteriopathy in the development and severity of reperfusion pulmonary edema after pulmonary endarterectomy. Pulmonary Circulation, 2019, 9, 1-9.	0.8	6
41	Characterization of pulmonary intimal sarcoma cells isolated from a surgical specimen: In vitro and in vivo study. PLoS ONE, 2019, 14, e0214654.	1.1	2
42	Clinical characteristics and prognosis in patients with chronic thromboembolic pulmonary hypertension and a concomitant psychiatric disorder. Pulmonary Circulation, 2019, 9, 1-9.	0.8	7
43	<p>Single-use suvorexant for treating insomnia during overnight polysomnography in patients with suspected obstructive sleep apnea: a single-center experience</p> . Drug Design, Development and Therapy, 2019, Volume 13, 809-816.	2.0	5
44	Elevated levels of autoantibodies against EXD2 and PHAX in the sera of patients with chronic thromboembolic pulmonary hypertension. PLoS ONE, 2019, 14, e0211377.	1.1	5
45	Pulmonary Hypertension Exacerbated by Nintedanib Administration for Idiopathic Pulmonary Fibrosis. Internal Medicine, 2019, 58, 965-968.	0.3	8
46	Features of radiological and physiological findings in pulmonary capillary hemangiomatosis: an updated pooled analysis of confirmed diagnostic cases. Pulmonary Circulation, 2019, 9, 1-8.	0.8	3
47	Use of vasodilators for the treatment of pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: A systematic review. Respiratory Investigation, 2019, 57, 183-190.	0.9	14
48	Safety of diagnostic flexible bronchoscopy in patients with echocardiographic evidence of pulmonary hypertension. Respiratory Investigation, 2019, 57, 73-78.	0.9	7
49	Heart Rate and Oxygen Saturation Change Patterns During 6-min Walk Test in Subjects With Chronic Thromboembolic Pulmonary Hypertension. Respiratory Care, 2018, 63, 573-583.	0.8	8
50	Endothelial cells from pulmonary endarterectomy specimens possess a high angiogenic potential and express high levels of hepatocyte growth factor. BMC Pulmonary Medicine, 2018, 18, 197.	0.8	8
51	Impact of Arterial Stiffness on WatchPAT Variables in Patients With Obstructive Sleep Apnea. Journal of Clinical Sleep Medicine, 2018, 14, 319-325.	1.4	15
52	Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: A systematic review. Respiratory Investigation, 2018, 56, 332-341.	0.9	42
53	Long-Term Outcome of Chronic Thromboembolic Pulmonary Hypertension at a Single Japanese Pulmonary Endarterectomy Center. Circulation Journal, 2018, 82, 1428-1436.	0.7	23
54	Partial anomalous pulmonary venous return with dual drainage to the superior vena cava and left atrium with pulmonary hypertension. Respiratory Medicine Case Reports, 2018, 25, 112-115.	0.2	2

#	Article	IF	Citations
55	Circulating autoantibodies against neuroblastoma suppressor of tumorigenicity 1 (NBL1): A potential biomarker for coronary artery disease in patients with obstructive sleep apnea. PLoS ONE, 2018, 13, e0195015.	1.1	12
56	V. Pulmonary Hypertension Associated with Respiratory Diseases. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 226-233.	0.0	0
57	Mosaic attenuation pattern in non-contrast computed tomography for the assessment of pulmonary perfusion in chronic thromboembolic pulmonary hypertension. Respiratory Investigation, 2017, 55, 300-307.	0.9	17
58	The dilatation of main pulmonary artery and right ventricle observed by enhanced chest computed tomography predict poor outcome in inoperable chronic thromboembolic pulmonary hypertension. European Journal of Radiology, 2017, 94, 70-77.	1.2	16
59	Endothelial cell-related autophagic pathways in Sugen/hypoxia-exposed pulmonary arterial hypertensive rats. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 313, L899-L915.	1.3	24
60	The anticoagulant effects of warfarin and the bleeding risk associated with its use in patients with chronic thromboembolic pulmonary hypertension at a specialist center in Japan: a retrospective cohort study. Pulmonary Circulation, 2017, 7, 684-691.	0.8	10
61	Riociguat for patients with chronic thromboembolic pulmonary hypertension: Usefulness of transitioning from phosphodiesterase type 5 inhibitor. Respiratory Investigation, 2017, 55, 270-275.	0.9	16
62	Prognostic and pathophysiological marker for patients with chronic thromboembolic pulmonary hypertension: Usefulness of diffusing capacity for carbon monoxide at diagnosis. Respirology, 2017, 22, 179-186.	1.3	22
63	The Development of Marked Collateral Circulation due to Inferior Vena Cava Filter Occlusion in a Patient with Chronic Thromboembolic Pulmonary Hypertension Complicated with Anti-phospholipid Syndrome. Internal Medicine, 2017, 56, 931-936.	0.3	4
64	Adult Partial Anomalous Pulmonary Venous Connection With Drainage to Left Atrium and Inferior Vena Cava Clearly Visualized on a Combination of Multiple Imaging Techniques. Circulation Journal, 2017, 81, 1547-1549.	0.7	2
65	Circulating Anti-Coatomer Protein Complex Subunit Epsilon (COPE) Autoantibodies as a Potential Biomarker for Cardiovascular and Cerebrovascular Events in Patients with Obstructive Sleep Apnea. Journal of Clinical Sleep Medicine, 2017, 13, 393-400.	1.4	12
66	Severe Pulmonary Arteriopathy Is Associated with Persistent Hypoxemia after Pulmonary Endarterectomy in Chronic Thromboembolic Pulmonary Hypertension. PLoS ONE, 2016, 11, e0161827.	1.1	10
67	Moyamoya disease and artery tortuosity as rare phenotypes in a patient with an elastin mutation. American Journal of Medical Genetics, Part A, 2016, 170, 1924-1927.	0.7	3
68	Prominin-1/CD133 expression as potential tissue-resident vascular endothelial progenitor cells in the pulmonary circulation. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 310, L1130-L1142.	1.3	20
69	Right ventricular sugars and fats in chronic thromboembolic pulmonary hypertension. International Journal of Cardiology, 2016, 219, 143-149.	0.8	5
70	Importance of carefully interpreting computed tomography images to detect partial anomalous pulmonary venous return. Respiratory Investigation, 2016, 54, 69-74.	0.9	12
71	Pulmonary haemodynamics are correlated with intimal lesions in a rat model of severe PAH: attenuation of pulmonary vascular remodelling with ambrisentan. Histology and Histopathology, 2016, 31, 1357-65.	0.5	4
72	Features of REM-related Sleep Disordered Breathing in the Japanese Population. Internal Medicine, 2015, 54, 1481-1487.	0.3	17

#	Article	IF	Citations
73	Noninvasive assessment of pulmonary vascular resistance by echocardiography in chronic thromboembolic pulmonary hypertension. Respiratory Investigation, 2015, 53, 210-216.	0.9	8
74	Determinants of an elevated pulmonary arterial pressure in patients with pulmonary arterial hypertension. Respiratory Research, 2015, 16, 84.	1.4	14
75	Hypoxia-induced proliferation of tissue-resident endothelial progenitor cells in the lung. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 308, L746-L758.	1.3	24
76	Vascular Repair by Tissue-Resident Endothelial Progenitor Cells in Endotoxin-Induced Lung Injury. American Journal of Respiratory Cell and Molecular Biology, 2015, 53, 500-512.	1.4	56
77	Increased Right Ventricular Fatty Acid Accumulation in Chronic Thromboembolic Pulmonary Hypertension. Annals of the American Thoracic Society, 2015, 12, 1465-1472.	1.5	12
78	Evaluation of the Microcirculation in Chronic Thromboembolic Pulmonary Hypertension Patients: The Impact of Pulmonary Arterial Remodeling on Postoperative and Follow-Up Pulmonary Arterial Pressure and Vascular Resistance. PLoS ONE, 2015, 10, e0133167.	1.1	26
79	The Role of Matrix Metalloproteinase in the Intimal Sarcoma-Like Cells Derived from Endarterectomized Tissues from a Chronic Thromboembolic Pulmonary Hypertension Patient. PLoS ONE, 2014, 9, e87489.	1.1	9
80	Electrocardiogram-Gated 320-Slice Multidetector Computed Tomography for the Measurement of Pulmonary Arterial Distensibility in Chronic Thromboembolic Pulmonary Hypertension. PLoS ONE, 2014, 9, e111563.	1.1	12
81	Pentraxin3 in Chronic Thromboembolic Pulmonary Hypertension: A New Biomarker for Screening from Remitted Pulmonary Thromboembolism. PLoS ONE, 2014, 9, e113086.	1.1	14
82	Home-based pulmonary rehabilitation in patients with inoperable or residual chronic thromboembolic pulmonary hypertension: A preliminary study. Respiratory Investigation, 2014, 52, 357-364.	0.9	50
83	The vascular bed in COPD: pulmonary hypertension and pulmonary vascular alterations. European Respiratory Review, 2014, 23, 350-355.	3.0	72
84	The effects of emphysema on airway disease: Correlations between multi-detector CT and pulmonary function tests in smokers. European Journal of Radiology, 2014, 83, 1022-1028.	1.2	13
85	Long-term Survival of Japanese Patients with Pulmonary Arterial Hypertension Treated with Beraprost Sodium, an Oral Prostacyclin Analogue. Internal Medicine, 2014, 53, 1913-1920.	0.3	6
86	Role of 320-Slice CT Imaging in the Diagnostic Workup of Patients With Chronic Thromboembolic Pulmonary Hypertension. Chest, 2013, 143, 1070-1077.	0.4	86
87	Crosstalk between endothelial cell and thrombus in chronic thromboembolic pulmonary hypertension: perspective. Histology and Histopathology, 2013, 28, 185-93.	0.5	16
88	Subpleural Perfusion as a Predictor for a Poor Surgical Outcome in Chronic Thromboembolic Pulmonary Hypertension. Chest, 2012, 141, 929-934.	0.4	31
89	Molecular mechanisms of lung-specific toxicity induced by epidermal growth factor receptor tyrosine kinase inhibitors. Oncology Letters, 2012, 4, 865-867.	0.8	13
90	Survival of Japanese Patients with Pulmonary Arterial Hypertension after the Introduction of Endothelin Receptor Antagonists and/or Phosphodiesterase Type-5 Inhibitors. Internal Medicine, 2012, 51, 2721-2726.	0.3	7

#	Article	IF	CITATIONS
91	Plasma proteomic analysis in patients with obstructive sleep apnea syndrome. Sleep and Biological Rhythms, 2012, 10, 336-339.	0.5	3
92	Vascular remodeling in pulmonary arterial hypertension: Multiple cancer-like pathways and possible treatment modalities. International Journal of Cardiology, 2011, 147, 4-12.	0.8	93
93	The importance of epigenetics in the development of chronic obstructive pulmonary disease. Respirology, 2011, 16, 1056-1063.	1.3	29
94	Endothelial-like cells in chronic thromboembolic pulmonary hypertension: crosstalk with myofibroblast-like cells. Respiratory Research, 2011, 12, 109.	1.4	53
95	The Effects of Antiangiogenic Compound SU5416 in a Rat Model of Pulmonary Arterial Hypertension. Respiration, 2011, 81, 253-261.	1.2	62
96	The estrogen paradox in pulmonary arterial hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2010, 299, L435-L438.	1.3	15
97	Reversible or Irreversible Remodeling in Pulmonary Arterial Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2010, 43, 629-634.	1.4	139
98	Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiation. Respiratory Research, 2009, 10, 95.	1.4	174
99	Dilatation of Bronchial Arteries Correlates With Extent of Central Disease in Patients With Chronic Thromboembolic Pulmonary Hypertension. Circulation Journal, 2008, 72, 1136-1141.	0.7	56
100	VEGFâ€R blockade causes endothelial cell apoptosis, expansion of surviving CD34 + precursor cells and transdifferentiation to smooth muscleâ€like and neuronalâ€like cells. FASEB Journal, 2007, 21, 3640-3652.	0.2	80
101	Vascular Endothelial Growth Factor and the Risk of Smoking-Related COPD. Chest, 2003, 124, 323-327.	0.4	39
102	Association of Tumor Necrosis Factor- \hat{l}_{\pm} Gene Promoter Polymorphism With Low Attenuation Areas on High-Resolution CT in Patients With COPD. Chest, 2002, 122, 416-420.	0.4	82
103	Thermoradiotherapy for local control of chest wall invasion in patients with advanced non-small cell lung cancer. International Journal of Clinical Oncology, 2002, 7, 343-348.	1.0	5
104	Clinical Outcomes of Sotrovimab Treatment in 10 High-Risk Patients with Mild COVID-19: A Case Series. American Journal of Case Reports, 0, 23, .	0.3	0